UK approves Regeneron/Roche antibody cocktail for Covid-19

The UK drug regulator has approved an antibody cocktail developed by Regeneron and Roche to prevent and treat Covid-19, it said on Friday, as the nation battles rising hospitalizations due to the more infectious Delta variant.

The medicines and healthcare products regulatory agency (MHRA) said clinical trial data shows the drug Ronapreve could help prevent infection, help resolve symptoms of severe Covid-19 infection and reduce the chances of hospitalization.

“This treatment will be a significant addition to our armoury to tackle Covid-19,” British health minister Sajid Javid said in a statement.

The news comes as hospitalizations of Covid-19 patients exceeded 6,100 this week, a five-month high. Two thirds of hospitalized patients were not vaccinated, data showed earlier this month.

Ronapreve, known as REGEN-COV in the United States, can be taken via injection or infusion. It binds tightly to the coronavirus at the lining of the respiratory system and prevents it from gaining access to cells of the respiratory system, the MHRA said.

Ronapreve belongs to a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the body to fight off infections. The drug is not intended to be used as a substitute for vaccination, the MHRA said.

Javid said the government would start to roll out the therapy across the NHS as soon as possible.

It’s the third therapy in the UK’s arsenal in addition to generic steroid dexamethasone and arthritis drug tocilizumab, sold by Roche as Actemra and RoActemra.

Earlier this week, Roche warned of a global shortage of its arthritis drug which will last a few more weeks.

Ronapreve/REGEN-COV received emergency approval to treat Covid-19 in more than 20 countries including the United States, which has also authorized a similar treatment by Eli Lilly for non-hospitalized Covid-19 patients.

It has been a big earner for Regeneron, which logged US sales of US$2.59 billion in the second quarter.

In June, the European Union bought about 55,000 doses of the treatment while the region’s drug watchdog reviews the drug for approval. – Reuters

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.